8-K: Ionis Pharmaceuticals Q2 2026 Results Show Growth, Pipeline Progress

Ionis Pharmaceuticals reported second quarter 2026 financial results, highlighting strong commercial revenue growth, progress in key drug development programs, and reaffirming its 2026 financial guidance.

Summary

• Ionis Pharmaceuticals announced its financial results for the second quarter ended June 30, 2026.
• Total revenue for the quarter was $268 million, a decrease from $452 million in the same period last year, primarily due to a large upfront payment received in Q2 2025.
• However, excluding the one-time sapablursen upfront payment, revenue increased by 56% year-over-year.
• Operating expenses were $370 million, up from $312 million in Q2 2025, attributed to increased investments in commercialization and launch preparations.
• The company ended the quarter with $2.1 billion in cash and short-term investments.
• Ionis is on track to achieve its 2026 financial guidance and its goal of cashflow breakeven in 2028.
• Key product updates include the early launch momentum for TRYNGOLZA (olezarsen) and continued strong sales for DAWNZERA (donidalorsen).
• Several important milestones are anticipated in the second half of 2026, including potential approvals and trial data readouts.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong commercial execution and pipeline progress, despite a GAAP revenue decrease due to a prior year's one-time event. The reaffirmation of guidance and positive outlook contribute to a favorable sentiment.

Positives

• TRYNGOLZA (olezarsen) is showing early launch momentum in severe hypertriglyceridemia (sHTG) and has generated $5 million in U.S. net product sales in Q2 2026.
• DAWNZERA (donidalorsen) generated $26 million in U.S. net product sales in Q2 2026, a 63% increase from the previous quarter.
• Full year 2026 product sales guidance for TRYNGOLZA is $100-110 million and for DAWNZERA is $110-120 million.
• Enrollment is complete for the Phase 3 REVEAL trial for obudanersen in Angelman syndrome, with data anticipated in the second half of 2027.
• The company is on track to achieve its 2026 financial guidance.
• Ionis is on track to achieve its goal of cashflow breakeven in 2028.
• SPINRAZA royalties were $54 million in Q2 2026, and WAINUA royalties were $16 million.
• Bepirovirsen for chronic hepatitis B has received Priority Review in the U.S. with a PDUFA target action date of October 26, 2026.

Negatives

• Total revenue for Q2 2026 was $268 million, down from $452 million in Q2 2025, largely due to a significant upfront payment received in the prior year's quarter.
• Operating expenses increased to $370 million in Q2 2026 from $312 million in Q2 2025, driven by increased commercialization and launch preparation investments.
• The Phase 3 CARDIO-TTRansform study of eplontersen for ATTR-CM missed its primary composite endpoint in the overall population, although it showed nominal significance in a pre-specified monotherapy population.
• Ionis reported a net loss of $115 million ($0.69 per share) for Q2 2026, compared to a net income of $124 million ($0.78 per share) in Q2 2025.

Risks

• The CARDIO-TTRansform study of eplontersen in ATTR-CM missed its primary endpoint, which could impact future development or commercialization of this indication.
• The company's forward-looking statements are subject to risks and uncertainties inherent in drug discovery, development, and commercialization.
• Future results could differ materially from forward-looking statements if assumptions do not materialize or prove correct.
• Regulatory reviews and approvals for pipeline candidates are subject to inherent uncertainties and timelines.

Future Outlook

Ionis Pharmaceuticals is on track to achieve its 2026 financial guidance and its goal of cashflow breakeven in 2028. The company anticipates multiple important milestones in the second half of 2026, including potential approvals for zilganersen and bepirovirsen, and expects results from the pelacarsen Lp(a) HORIZON trial. Management expects accelerating growth from TRYNGOLZA and other wholly owned medicines.

Management Comments

• "With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accelerating growth from TRYNGOLZA and our other wholly owned medicines in the quarters and years to come."
• "In the second half of this year, we expect multiple important milestones, including approval of zilganersen for Alexander disease, positioning us for our first independent launch from our leading neurology portfolio. We also expect results from the landmark pelacarsen Lp(a) HORIZON cardiovascular outcomes trial and the global launch of bepirovirsen for chronic hepatitis B."
• "With our advancing pipeline and growing commercial momentum, Ionis is on track to deliver accelerating value to patients and all Ionis stakeholders."
• "Our performance in the first half of this year reflects the strength and resilience of our business. We delivered significantly increased commercial revenue from our independent launches, substantial R&D revenue from multiple partnered medicines and invested in our advancing wholly owned pipeline."
• "Even with the outcome of the CARDIO-TTRansform study of eplontersen in ATTR-CM, our first-half execution and positive outlook for the second half of the year keep us on track to achieve our 2026 financial guidance. We also remain on track to achieve our goal of cashflow breakeven in 2028 and deliver substantial growth and long-term value-creation."

Industry Context

StockSavvy.ai notes that Ionis Pharmaceuticals' focus on RNA-targeted therapies positions it within a rapidly evolving and high-potential segment of the biopharmaceutical industry. The company's progress with TRYNGOLZA and DAWNZERA, alongside its robust pipeline, reflects a strategy to build a diversified portfolio of innovative treatments for rare and serious diseases, a trend seen across many leading biotech firms.

Comparison to Industry Standards

• Ionis's revenue decline in Q2 2026 compared to Q2 2025, while significant on a GAAP basis, is explained by a large one-time upfront payment in the prior year. Excluding this, the 56% revenue growth indicates strong underlying commercial performance, which is a positive indicator compared to many peers facing market access challenges.
• The company's investment in R&D and commercialization, leading to increased operating expenses, is typical for biopharmaceutical companies advancing multiple pipeline candidates and launching new products. This level of investment is necessary to compete and innovate in the sector.
• The miss on the primary endpoint for the CARDIO-TTRansform study, while disappointing, is a common occurrence in late-stage clinical trials for complex cardiovascular diseases. Many companies experience similar setbacks, and the ability to pivot or find success in sub-populations is a key differentiator.

Stakeholder Impact

• Shareholders: Potential for increased value driven by commercial growth and pipeline advancements, though offset by near-term GAAP revenue decline and operational investments.
• Patients: Access to new treatments like TRYNGOLZA for sHTG and potential future therapies for Angelman syndrome, Alexander disease, and chronic hepatitis B.
• Employees: Continued investment in R&D and commercialization may lead to growth and opportunities within the company.
• Creditors: The company's cash position of $2.1 billion provides a buffer for ongoing operations and debt obligations.

Next Steps

• Continue commercialization efforts for TRYNGOLZA and DAWNZERA.
• Prepare for the potential launch of zilganersen for Alexander disease in the U.S. (pending approval).
• Prepare for the global launch of bepirovirsen for chronic hepatitis B.
• Present data from CORE and CORE2 studies for TRYNGOLZA at the European Society of Cardiology (ESC) Congress in August 2026.
• Present data from the CARDIO-TTRansform study for eplontersen at the ESC Congress in August 2026.
• Present data from the Phase 1 study of ION775 at the ESC Congress in August 2026.
• Advance obudanersen into data analysis for the Phase 3 REVEAL study.
• Continue development and regulatory submissions for various pipeline programs.

Key Dates

Recommendation

The company is executing well on its commercial products and advancing its pipeline, but the GAAP revenue decline and the miss on a key clinical trial endpoint warrant a cautious approach. While the long-term outlook is positive, near-term uncertainties and the need for further clinical validation suggest a 'hold' rating until more data is available and commercial momentum for new launches is fully established.

Keywords

RNA-targeted medicines, severe hypertriglyceridemia, hereditary angioedema, transthyretin-mediated amyloidosis, Angelman syndrome, Alexander disease, chronic hepatitis B, drug development